Fernando Edington1, Douglas Varjão2, Paulo Melo2. 1. Universidade Estadual de Santa Cruz, Campus Soane Nazaré de Andrade, Rodovia Jorge Amado, Km 16, Bairro Salobrinho, CEP 45662-900, Ilhéus-Bahia, Brazil. Electronic address: flbedington@uesc.br. 2. Universidade Estadual de Santa Cruz, Campus Soane Nazaré de Andrade, Rodovia Jorge Amado, Km 16, Bairro Salobrinho, CEP 45662-900, Ilhéus-Bahia, Brazil.
Abstract
OBJECTIVE: To estimate the incidence of chronic articular symptoms after chikungunya virus infection of patients from the American continent. METHODS: We performed a systematic review of the literature using the MEDLINE, Web of Science and Scopus databases. We included only cohort studies conducted in the American continent reporting the incidence of chronic articular symptoms after chikungunya virus acute infection. The quality of the selected studies was evaluated through the Newcastle-Ottawa Scale for non-randomized studies and relevant data were extracted. The pooled incidence of post-chikungunya chronic symptoms was estimated using a random-effect model meta-analysis. Heterogeneity was assessed by Q of Cochrane and its P-value, Tau2 and I2. Subgroup analysis was performed, and studies were stratified by quality, sample size, region, country, period of follow-up and study design. RESULTS: Up to February 24, 2018, a total of 1115 potentially relevant studies were identified through our search strategy. After exclusion of 226 duplicates and 845 irrelevant studies, we retrieved 41 articles for full-text appreciation, from which 18 studies met our inclusion criteria and were included in this systematic review. Our meta-analysis suggests that 52% of the patients infected with the chikungunya virus will present chronic articular symptoms, although a high heterogeneity between studies was also found (I2 = 94%). CONCLUSION: Fifty-two percent of chikungunya infected patients in the American continent are expected to develop the chronic stage of the disease. Chikungunya fever needs to be dealt as a major world health problem.
OBJECTIVE: To estimate the incidence of chronic articular symptoms after chikungunya virus infection of patients from the American continent. METHODS: We performed a systematic review of the literature using the MEDLINE, Web of Science and Scopus databases. We included only cohort studies conducted in the American continent reporting the incidence of chronic articular symptoms after chikungunya virus acute infection. The quality of the selected studies was evaluated through the Newcastle-Ottawa Scale for non-randomized studies and relevant data were extracted. The pooled incidence of post-chikungunya chronic symptoms was estimated using a random-effect model meta-analysis. Heterogeneity was assessed by Q of Cochrane and its P-value, Tau2 and I2. Subgroup analysis was performed, and studies were stratified by quality, sample size, region, country, period of follow-up and study design. RESULTS: Up to February 24, 2018, a total of 1115 potentially relevant studies were identified through our search strategy. After exclusion of 226 duplicates and 845 irrelevant studies, we retrieved 41 articles for full-text appreciation, from which 18 studies met our inclusion criteria and were included in this systematic review. Our meta-analysis suggests that 52% of the patients infected with the chikungunya virus will present chronic articular symptoms, although a high heterogeneity between studies was also found (I2 = 94%). CONCLUSION: Fifty-two percent of chikungunya infectedpatients in the American continent are expected to develop the chronic stage of the disease. Chikungunya fever needs to be dealt as a major world health problem.
Authors: Allison August; Husain Z Attarwala; Sunny Himansu; Shiva Kalidindi; Sophia Lu; Rolando Pajon; Shu Han; Jean-Michel Lecerf; Joanne E Tomassini; Marjie Hard; Leon M Ptaszek; James E Crowe; Tal Zaks Journal: Nat Med Date: 2021-12-09 Impact factor: 53.440
Authors: Simone de Araújo; Victor R de Melo Costa; Franciele M Santos; Carla D Ferreira de Sousa; Thaiane P Moreira; Matheus R Gonçalves; Franciel B Félix; Celso M Queiroz-Junior; Gabriel H Campolina-Silva; Maurício Lacerda Nogueira; Michelle A Sugimoto; Caio S Bonilha; Mauro Perretti; Danielle G Souza; Vivian V Costa; Mauro M Teixeira Journal: Cells Date: 2022-08-31 Impact factor: 7.666
Authors: Eranga Abeyratne; Kothila Tharmarajah; Joseph R Freitas; Helen Mostafavi; Suresh Mahalingam; Ali Zaid; Mehfuz Zaman; Adam Taylor Journal: Front Immunol Date: 2020-03-05 Impact factor: 7.561